Coave Therapeutics and Théa Open Innovation sign exclusive licensing, codevelopment and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa.
Théa and Kiora Pharmaceuticals sign a new partnership
1 February 2024